Through integrated network pharmacology and experimental validation, it was demonstrated that FBB protects against ALI via a multi-target mechanism, primarily modulating the PI3K/AKT, MAPK, and NF-κB pathways. Here, NFKB1 is linked to acute respiratory distress syndrome.